Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer

Colorectal cancer (CRC), ranking third in incidence among men and second in women globally with third-highest mortality in the US, remains a major health challenge despite multimodal therapies, particularly for advanced-stage patients with poor prognosis where immune checkpoint inhibitors (ICIs) like PD-1/PD-L1 blockers have emerged as transformative agents by reinvigorating anti-tumor immunity through PD-1/PD-L1 pathway inhibition. While MSI-H CRC's high mutational burden renders it susceptible to immunotherapy, clinical trials demonstrate durable responses with domestic ICIs such as tisleliz

Trial Details

NCT ID
NCT07076823
Phase
PHASE1
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Canagliflozin
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Aged ≥18 years and ≤80 years old at the time of signing the written informed consent form, regardless of gender.
  • Patients with histologically or cytologically confirmed colorectal cancer, including:
  • Patients with unresectable locally advanced, recurrent, or distant metastatic colorectal cancer.
  • Patients with wild-type RAS/RAF and BRAF V600E genotypes in tumor tissues.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →